Sham Stimulation ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 1 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05003310 (ClinicalTrials.gov) | October 19, 2021 | 5/7/2021 | Splenic Stimulation for RA | Multipart Exploratory Study to Evaluate Splenic Nerve Stimulation in Patients With Rheumatoid Arthritis | Rheumatoid Arthritis | Device: Active Stimulation;Device: Sham Stimulation;Drug: Baricitinib;Drug: Background Treatment | Galvani Bioelectronics | NAMSA;Q2 Solutions | Recruiting | 22 Years | 75 Years | All | 28 | N/A | United States |